> Details

Pellini, Raul; Venuti, Aldo; Pimpinelli, Fulvia; Abril, Elva; Blandino, Giovanni; Campo, Flaminia; Conti, Laura; De Virgilio, Armando; De Marco, Federico; Di Domenico, Enea Gino; Di Bella, Ornella; Di Martino, Simona; Ensoli, Fabrizio; Giannarelli, Diana; Mandoj, Chiara; Manciocco, Valentina; Marchesi, Paolo; Mazzola, Francesco; Moretto, Silvia; Petruzzi, Gerardo; Petrone, Fabrizio; Pichi, Barbara; Pontone, Martina; Zocchi, Jacopo; [...]

Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI
  • Contributor: Pellini, Raul; Venuti, Aldo; Pimpinelli, Fulvia; Abril, Elva; Blandino, Giovanni; Campo, Flaminia; Conti, Laura; De Virgilio, Armando; De Marco, Federico; Di Domenico, Enea Gino; Di Bella, Ornella; Di Martino, Simona; Ensoli, Fabrizio; Giannarelli, Diana; Mandoj, Chiara; Manciocco, Valentina; Marchesi, Paolo; Mazzola, Francesco; Moretto, Silvia; Petruzzi, Gerardo; Petrone, Fabrizio; Pichi, Barbara; Pontone, Martina; Zocchi, Jacopo; [...]
  • imprint: MDPI AG, 2021
  • Published in: Vaccines
  • Language: English
  • DOI: 10.3390/vaccines9070685
  • ISSN: 2076-393X
  • Keywords: Pharmacology (medical) ; Infectious Diseases ; Drug Discovery ; Pharmacology ; Immunology
  • Origination:
  • Footnote:
  • Description: <jats:p>Background: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation with age, gender and body mass index (BMI). Methods: Participants had a nasopharyngeal swab for SARS-CoV-2 and were assessed for the presence of SARS-CoV-2 antibodies at baseline and 21 days after the BNT162b2 priming dose. Results: First dose of BNT162b2 activated immune responses in 98% of the participants. Five HWC had no increase in antibody titre 21 days after the first dose. Antibody titre was greater in young (&lt;38 years) vs. older participants (&lt;38 vs. 47–56 p = 0.002; &lt;38 vs. &gt;56 p = 0.001). Higher antibody levels were detected in underweight vs. pre-obesity group (p = 0.026) and in normal-weight vs. pre-obesity group (p = 0.007). This association was confirmed after adjusting for age (p = 0.0001) and gender (p = 0.00001). Conclusions: Our study demonstrates that a single dose of BNT162b2 activates the immune response, and being young and normal-weight correlate positively with this response. Larger specifically designed clinical trials are needed to validate these results.</jats:p>
  • Access State: Open Access